Cardinal Health, Inc. (CAH) - Fiscal 2026 10-K Summary
Business Context and Reporting Period
This summary covers Cardinal Health, Inc.'s Annual Report on Form 10-K for the fiscal year ended June 30, 2026. Cardinal Health is a global healthcare services and products company operating primarily through two reportable segments: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD). The "Other" segment includes Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. The company serves hospitals, healthcare systems, pharmacies, and patients in the home.
Key Financial Metrics
| Metric | Fiscal 2026 | Fiscal 2025 | Change |
|---|---|---|---|
| Total Revenue | $254.2 billion | $222.6 billion | +14% |
| GAAP Operating Earnings | $2.6 billion | $2.3 billion | +15% |
| Non-GAAP Operating Earnings | $3.6 billion | $2.8 billion | +30% |
| GAAP Diluted EPS | $7.23 | $6.45 | +12% |
| Non-GAAP Diluted EPS | $11.26 | $8.24 | +37% |
| Net Earnings (GAAP) | $1.7 billion | $1.6 billion | +10% |
| Operating Cash Flow | $5.2 billion | $2.4 billion | +117% |
| Cash and Equivalents | $4.9 billion | $3.9 billion | N/A |
| Total Long-Term Debt | $8.9 billion | $8.5 billion | N/A |
| Effective Tax Rate | 21.6% | 25.3% | -3.7 pts |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by a 15% increase in the Pharma segment ($234.8 billion) due to branded and specialty pharmaceutical sales growth. The GMPD segment remained relatively flat (+1%) at $12.7 billion, while the "Other" segment grew 26% to $6.8 billion.
- Profitability: GAAP operating earnings increased 15%, but Non-GAAP operating earnings surged 30%. The divergence is largely due to a $184 million goodwill impairment charge in the Navista & ION reporting unit and a $122 million impairment of an equity interest in Outcomes, which were excluded from Non-GAAP measures.
- Acquisitions: Significant M&A activity included the acquisition of Solaris Health (a urology MSO) for ~$1.9 billion, Advanced Diabetes Supply Group (ADS) for ~$1.0 billion, and GI Alliance for ~$2.8 billion. These acquisitions contributed to segment profit growth.
- Tariffs: The company recorded a receivable of approximately $200 million for expected refunds of IEEPA tariffs paid in the prior year. While this provided a net benefit of ~$100 million in Q4, the overall impact on fiscal 2026 operating earnings was immaterial due to timing.
- Interest Expense: Net interest expense increased 62% to $348 million, primarily due to additional debt financing for recent acquisitions.
Guidance, Outlook, and Risks
- Outlook: Management expects demand growth for GLP-1 medications to moderate in future periods. Capital expenditures for fiscal 2027 are expected to be approximately $700 million.
- Tariff Risks: The company faces ongoing uncertainty regarding tariffs on branded and generic pharmaceuticals. A proclamation in April 2026 imposed tariffs on branded imports, and potential tariffs on generics (100% in 2028, 200% in 2029) remain a risk. The company is taking actions to mitigate costs but notes that measures have not fully offset adverse impacts.
- Regulatory & Legal:
- Opioid Litigation: The company has $4.3 billion accrued for opioid-related settlements, with payments expected through 2038. Annual payments under the National Opioid Settlement Agreement (NOSA) continue.
- Tax Audits: The IRS issued Notices of Proposed Adjustment (NOPA) regarding self-insurance loss carrybacks and a restructuring transaction, potentially resulting in additional tax liabilities of approximately $1.4 billion and $160 million, respectively. Management believes reserves are sufficient but outcomes are uncertain.
- Goodwill Impairment: Future impairments remain a risk if reporting units fail to meet financial plans or if discount rates increase.
- MSO Strategy: The company is expanding its Managed Service Organization (MSO) platforms (The Specialty Alliance, Navista). Success depends on integration, provider retention, and navigating regulatory environments regarding corporate ownership of physician practices.
Investor Verification Checklist
- Goodwill Impairment Sensitivity: Verify the assumptions used in the Navista & ION impairment test (discount rate of 10.5%, terminal growth of 3%) and assess the risk of further impairments if these assumptions change.
- Tax Contingencies: Review the details of the IRS NOPAs regarding the $1.4 billion potential liability and the company's reserve adequacy.
- Tariff Exposure: Monitor the implementation of new tariffs on branded and generic pharmaceuticals and the company's ability to pass costs to customers.
- Opioid Settlement Payments: Track the schedule of future payments under the NOSA and any new private plaintiff litigation developments.
- MSO Integration: Assess the financial performance and integration progress of recent MSO acquisitions (Solaris Health, GIA, ADS) against strategic expectations.